During the reporting period, an organisational restructure was undertaken to respond to the evolving needs and priorities of the organisation. Most significantly, a Chief Operating Officer was appointed, with responsibility for safety and other responsibilities as outlined below, and a Nuclear Precinct established at the Lucas Heights campus. The Nuclear Precinct, under the leadership of Ms Pamela Naidoo-Ameglio, consolidates the operational functions of ANSTO Nuclear Medicine Pty Limited, Health Products, Reactor Operations and Waste Management.
Subsidiaries and companies
ANSTO has the following subsidiaries and company (where ANSTO possesses a material interest)
Jurisdiction of operation
PETTECH Solutions Pty Ltd
PETTECH Solutions Pty Ltd is a small nuclear medicine diagnostic company and wholly owned ANSTO subsidiary. Its business operations were sold to Cyclotek NSW under a collaborative venture which will strengthen the PET imaging market and increase the research and development capability for new nuclear medicine diagnostics in New South Wales.
ANSTO Nuclear Medicine Pty Ltd
ANSTO Nuclear Medicine Pty Ltd is the operating producer of one of the world’s most important nuclear medicines, Mo-99. The subsidiary will also participate and invest in nuclear medicine and related activities, including applied research and development aligned and complementary to its core facilities and competencies.
Applied Molecular Therapies Pty Ltd
Contract development and manufacturer of radiopharmaceutical products